BR112014010376A2 - medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima - Google Patents

medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima

Info

Publication number
BR112014010376A2
BR112014010376A2 BR112014010376A BR112014010376A BR112014010376A2 BR 112014010376 A2 BR112014010376 A2 BR 112014010376A2 BR 112014010376 A BR112014010376 A BR 112014010376A BR 112014010376 A BR112014010376 A BR 112014010376A BR 112014010376 A2 BR112014010376 A2 BR 112014010376A2
Authority
BR
Brazil
Prior art keywords
rebamipide
medicament
eye disease
anterior eye
retention agent
Prior art date
Application number
BR112014010376A
Other languages
English (en)
Inventor
Nakashima Hideo
Urashima Hiroki
Shinohara Hisashi
Takeji Yasuhiro
Hirata Yuki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014010376(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112014010376A2 publication Critical patent/BR112014010376A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima". a presente invenção refere-se a uma combinação de rebamipida e a um agente de retenção de lágrimas como um medicamento para o tratamento de doenças do olho anterior.
BR112014010376A 2011-11-01 2012-10-31 medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima BR112014010376A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011240177 2011-11-01
PCT/JP2012/078769 WO2013065866A1 (en) 2011-11-01 2012-10-31 A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent

Publications (1)

Publication Number Publication Date
BR112014010376A2 true BR112014010376A2 (pt) 2017-04-25

Family

ID=47215697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010376A BR112014010376A2 (pt) 2011-11-01 2012-10-31 medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima

Country Status (18)

Country Link
US (1) US20140294991A1 (pt)
EP (1) EP2773350A1 (pt)
JP (1) JP6060168B2 (pt)
KR (1) KR101951511B1 (pt)
CN (1) CN103945846A (pt)
AR (1) AR088585A1 (pt)
AU (1) AU2012333448A1 (pt)
BR (1) BR112014010376A2 (pt)
CA (1) CA2851095A1 (pt)
CO (1) CO6960545A2 (pt)
EA (1) EA201490721A1 (pt)
HK (1) HK1198811A1 (pt)
IL (1) IL231922A0 (pt)
IN (1) IN2014CN03123A (pt)
MX (1) MX2014005209A (pt)
SG (1) SG11201401502TA (pt)
TW (1) TW201322982A (pt)
WO (1) WO2013065866A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081173B2 (ja) * 2011-12-12 2017-02-15 ロート製薬株式会社 眼科用水性組成物
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Lttバイオファーマ ドライアイ改善剤
KR20170039347A (ko) * 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
WO2020138135A1 (ja) 2018-12-26 2020-07-02 ライオン株式会社 眼科用組成物
WO2023054669A1 (ja) * 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084225A (ja) * 1983-10-17 1985-05-13 Hiroko Shimizu 点眼剤
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
TWI363626B (en) 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
US8388995B1 (en) * 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
US8158679B2 (en) * 2006-12-11 2012-04-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
PL2285413T3 (pl) 2008-06-19 2013-01-31 Otsuka Pharma Co Ltd Kompozycja farmaceutyczna
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration

Also Published As

Publication number Publication date
MX2014005209A (es) 2014-05-28
EP2773350A1 (en) 2014-09-10
SG11201401502TA (en) 2014-09-26
EA201490721A1 (ru) 2014-08-29
IN2014CN03123A (pt) 2015-07-03
JP6060168B2 (ja) 2017-01-11
HK1198811A1 (en) 2015-06-12
AU2012333448A1 (en) 2014-05-22
KR20140087030A (ko) 2014-07-08
CN103945846A (zh) 2014-07-23
CA2851095A1 (en) 2013-05-10
TW201322982A (zh) 2013-06-16
CO6960545A2 (es) 2014-05-30
WO2013065866A1 (en) 2013-05-10
US20140294991A1 (en) 2014-10-02
IL231922A0 (en) 2014-05-28
AR088585A1 (es) 2014-06-18
KR101951511B1 (ko) 2019-02-22
JP2014532641A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015022197A2 (pt) tratamento de cataplexia
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
BR112014014378A2 (pt) composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112013005438A2 (pt) "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo."
BR112014001118A2 (pt) combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
GT201400288A (es) "compuestos de fenoxietil piperidina"
BR112014019399A2 (pt) métodos de tratamento da fibrose
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
GT201400242A (es) "nuevos compuestos de pirazol"
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]